Close
Who We Are
Leadership Team
Board of Directors
Environmental, Social, and Governance (ESG) Commitment
Justice, Equity, Diversity, and Inclusion Commitment
Our Platform
Posters & Publications
Our Pipeline
Inflammatory Diseases
Patients, Families & Physicians
Investors & Media
News & Events
SEC Filings
Stock
Analyst Coverage
Governance
Careers
Contact Us
Skip to main content
Skip to footer
Evelo
Menu
A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer
Home
/
Posters
/
A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer
December 11, 2020
by
